Advanced search×

Drug Discovery Today

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
CSA, Rcgp, Proquest, Sciencedirect from 1996, Gale, and Ingenta

  1. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies

    Drug Discovery Today 20(10):1217 (2015) PMID 26100737

    Most oral antidiabetic drugs exhibit low oral bioavailability and need to be taken more than once daily owing to short half-lives, resulting in poor patient compliance. There is a necessity for improved drug delivery devices for antidiabetic agents because of the scale of their use and short-com...
  2. Sirolimus and everolimus in kidney transplantation

    Drug Discovery Today 20(10):1243 (2015) PMID 26050578

    • mTOR inhibitors have proven their efficacy and offer renal and antiviral benefits. • Sirolimus and everolimus differ mainly in pharmacokinetic characteristics. ...
  3. Therapeutic approaches of magnetic nanoparticles for the central nervous system

    Drug Discovery Today 20(10):1256 (2015) PMID 26103617

    • A CNS disease can result in neurological disorders. • Targeting across the blood–brain barrier for CNS therapy is challenging. ...
  4. Supporting malaria elimination with 21st century antimalarial agent drug discovery

    Drug Discovery Today 20(10):1265 (2015) PMID 26103616

    • To achieve malaria elimination novel treatments need to block disease transmission. • A new generation of antimalarial candidate drugs holds much promise. ...
  5. Impact of recent innovations in the use of mass cytometry in support of drug development

    Drug Discovery Today 20(10):1169 (2015) PMID 26092491

    • Recent innovation in CyTOF brings the capability for simultaneous detection of many proteins to single-cell biology. • CyTOF helps to profile each cell phenotypi...
  6. Challenges and opportunities for non-antibody scaffold drugs

    Drug Discovery Today 20(10):1271 (2015) PMID 26360055

    • Non-antibody scaffold drugs are a promising new class of biologics drugs. • The first candidate scaffolds are now moving into clinical development and practice. ...
  7. Contents page 1
    Author(s) unavailable

    Drug Discovery Today 20(10):i (2015)

  8. Cancer stem cells: a challenging paradigm for designing targeted drug therapies

    Drug Discovery Today 20(10):1205 (2015) PMID 26143148

    • New drug discovery and molecules in clinical development against cancer stem cells. • Surface marker, transcription factors and signal transduction pathways in C...
  9. Contents page 2
    Author(s) unavailable

    Drug Discovery Today 20(10):iii (2015)

  10. Compound Passport Service: supporting corporate collection owners in open innovation

    Drug Discovery Today 20(10):1250 (2015) PMID 26136162

    A growing number of early discovery collaborative agreements are being put in place between large pharma companies and partners in which the rights for assets can reside with a partner, exclusively or jointly. Our corporate screening collection, like many others, was built on the premise that co...